BCL2 and B-cell chronic lymphocytic leukemia: VPA perpetuates its effects by up-regulating cyclin-dependent kinase inhibitor 1A, BCLA1, and p53, whereas proto-oncogene (c-Myc, BCL2, BCL-XL, Ataxia-Telangiectasia Mutated, protein kinase B) were downregulated, thereby augmenting mTOR inhibitor to induce autophagic cell death in several kinds of lymphomas including Burkitt leukemia/lymphoma, cutaneous T cell lymphoma and CLL (153, 154).